Delete search term

To content

Main navigation

Zurich University
of Applied Sciences

Service navigation

Cost of illness: acute coronary syndrome in Switzerland

Description

QUESTIONS UNDER STUDY: To perform a cost-of-illness study of acute coronary syndrome (ACS) in Switzerland from a societal perspective, evaluating direct costs, production losses and intangible costs in terms of quality adjusted life years (QALYs) lost.
METHODS: A bottom-up incidence-based approach was used. Data concerning patients with one or more ACS
events were extracted from a national hospital database and from mortality statistics. Inpatient costs included acute care and rehabilitation. Outpatient costs included costs for ambulance, visits to GP and cardiologist, outpatient diagnostics, medication and rehabilitation. Production losses included absenteeism, permanent disability and premature death. Intangible costs were calculated on previously published QALY weights. Cost data were derived from official price lists, literature and experts. Future costs and QALYs lost were discounted.
RESULTS: In 2008 14,955 patients experienced a total of 16,815 ACS events; 2,752 died as a consequence of these. The resulting 19,064 hospital stays had an average acrosshospital length of stay of 9.1 days per patient. Total direct costs of ACS amounted to 630 Mio Swiss Francs (CHF) for society and CHF 462 Mio for health insurers. Total direct costs were dominated by costs of myocardial infarction: ST-elevation 45.8%, non-ST-elevation 35.8%. Production losses were CHF 519 Mio and intangible costs resulted in
49,878 QALYs lost.
CONCLUSIONS: ACS causes considerable costs in terms of direct medical expenditures, lost production, suffering and premature death, even without taking into account costs for its chronic consequences such as congestive heart failure.

Key data

Projectlead

Prof. Dr. Simon Wieser, Prof. Dr. Klaus Eichler

Project status

completed, 07/2010 - 12/2012

Institute/Centre

Winterthur Institute of Health Economics (WIG)

Funding partner

AstraZeneca AG

Project budget

100'000 CHF

Privacy Settings

Here we show you which services may run on our website. You decide for yourself which services we may use. You can find more information in our privacy notice.

Our website needs these cookies so that everything works properly. These cookies are created automatically when you are active on the site – for example, when you change privacy settings or fill in forms. You can block these cookies in your browser or set it to warn you about them, but some parts of the website will then no longer display correctly. These cookies do not store any of your personal data.

These services allow us to see how our website is used, but we do not know who you are. By activating these services, you help us make the website better for everyone.